Companies

Apr, 2023. AstraZeneca’s Gefurulimab injection(ALXN1720) obtains the Implied License from CDE for generalized myasthenia gravis clinical trial.

On March 10th, 2023， Beijing InnoCare announced that its independently developed BCL2 inhibitor ICP-248 completed the first subject administration in China. ICP-248 is a new oral highly selective BCL2 inhibitor independently developed by InnoCare. It is intended for the treatment of malignant hematological tumors such as non-Hodgkin’s lymphoma (NHL) and acute lymphoblastic leukemia (ALL) as a monotherapy or in combination with other drugs such as BTK inhibitors. ICP-248 is currently being investigated for B-cell malignancies, malignant hematologic tumors, and hematologic tumors. BCL2 is an oncogene with a significant role in…

Jan, 2023, Simnotrelvir Tablets/Ritonavir Tablets (co-packaged) submitted by Hainan Simcere Pharmaceutical Co., Ltd. received special drug approval as class 1 innovative drug for emergency application at China National Medical Products Administration (NMPA) with conditional requirements.

Top 10 Drugs Losing Patent Exclusivity in US Market in 2021 are Lucentis (Genentech/Roche), Bystolic (AbbVie/Allergan), Vascepa (Amarin), Nothera (Lundbeck), Narcan (Emergent Biosolutions), Brovana (Sunovion), Sutent (Pfizer), Saphris (AbbVie/Allergan), Amitiza (Mallinckrodt), and Feraheme (Amag Pharma).

China NMPA announced on that Utidelone injection (UTD1), applied by Chengdu Biostar Pharmaceuticals Ltd., has been approved to market on Mar 15th, 2021, which provides a new treatment option for metastatic breast cancer patients.

Trinomab Biotechnology Co., Ltd’s domestically developed human monoclonal antibody against tetanus toxin TNM002 has been officially approved by Human Research Ethics Committee (HREC) and Therapeutic Goods Administration (TGA) in Australia for the Phase I clinical trial.

China manufacturers accounts for a large proportio of ketoprofen API. Here we share Top Ketoprofen Manufacturers & Suppliers in China with good price level.

China is the largest market of Large Volume Parenteral Infusion Solutions in the world. Which are the Large Volume Parenteral Infusion Solutions manufacturers in China?  PharmArch shares the list based on our research.

By cooperating with the originator, Livezon successfully get marketing approval for iprazole enteric-coated tablets in 2007 and Iprazole sodium for injection in 2017. Now the products have rapid growth in China in 2020.

China NMPA has granted conditional approval for conditional approval for RemeGen’s Telitacicept (RC-18) with theraputic indiction of Systemic Lupus Erythematosus(SLE) on Mar 10, 2021.